Cipla's Former CEO Takes the Helm at Cohance Lifesciences

Cohance Lifesciences has handed its executive leadership to Umang Vohra, former CEO and Managing Director of Cipla Ltd, signaling a deliberate repositioning of the CDMO's ambitions in API manufacturing and complex molecule development. For pharma companies evaluating contract manufacturing partners, the appointment introduces a leader with deep operational experience across global regulatory environments and large-scale GMP-compliant manufacturing networks.

Vohra assumes the role of Executive Chairman effective May 1, 2026, and Group CEO effective May 20, 2026. He succeeds Vivek Sharma, who stepped down as Executive Chairman for personal reasons. Cohance confirmed Sharma will remain with the company in an advisory capacity for nine months to support transition continuity. The board described the appointment as a deliberate, strategic decision to bring in a leader whose profile is specifically suited to the demands of the company's transformation and its next phase of growth.

Cohance operates as a unified CDMO platform built through a series of strategic acquisitions, serving global pharmaceutical and biotechnology companies across APIs, complex molecules, specialty chemicals, and formulations. Vohra acknowledged the existing foundation: "Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation," adding that he intends to work closely with current management to create value for customers, employees, and shareholders.

For QA directors and regulatory affairs leads at companies with active or prospective Cohance partnerships, leadership transitions at CDMOs warrant close monitoring. Changes at the executive level can influence quality system priorities, ICH Q10 alignment, and the pace of technology transfer programs. How Vohra chooses to integrate his experience from a vertically integrated innovator like Cipla into a contract-focused platform will shape Cohance's operational posture in the near term.